RWJ-445380 Cathepsin-S inhibitor

RWJ-445380 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RWJ-445380 Cathepsin-S inhibitor, covering 2014-05-21 to 2014-05-21. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy [Phase 2]

See pricing